CTSU ECOG E1305: A PHASE III RANDOMIZED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER

Approval Date:
Principal Investigator:
Eligibility:

Approval Date: 8/31/2010

Principal Investigator: Padmaja Venuturumilli, MD

This randomized phase III trial is studying chemotherapy to see how well it works with or without bevacizumab in treating patients with recurrent or metastatic head and neck cancer.

Eligibility:

Each study has its own guidelines for who can participate, called "eligibility criteria", with only the study doctor able to determine if you meet all eligibility criteria. More information can be found at http://clinicaltrials.gov/ct2/show/NCT00588770

Contact Person:
CCTO Royal Oak
248-551-3230

Status of Clinical Trial:
open and enrolling

Contact Person:
Status of Clinical Trial:

Copyright © 2014 Beaumont Health System. All Rights Reserved. Privacy Policy | Site Map